SynthesisClinical journal of the American Society of Nephrology : CJASN2013
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.
Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03062813 (The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis), which is not on this map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.BMC nephrology · 2019Trial
- Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.Journal of the American Society of Nephrology : JASN · 2017Trial
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?Journal of nephrology · 2023Review
- Case report: Successful treatment of refractory membranous nephropathy with telitacicept.Frontiers in immunology · 2023Article
- Clinical and pathological analysis of renal biopsies of elderly patients in Northeast China: a single-center study.Renal failure · 2021Article
- Effect of mizoribine pulse therapy in adult membranous nephropathy.International urology and nephrology · 2021Article
- Membranous Nephropathy: From Research Bench to Personalized Care.Journal of clinical medicine · 2021Review
- Idiopathic Membranous Nephropathy and Treatment Related Complications.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
- Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.BMJ case reports · 2020Article
- Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis.International urology and nephrology · 2019Article
- Membranous Nephropathy in a Patient with Human Immunodeficiency Virus Shortly After Initiation of HAART with Atripla.Cureus · 2019Article
- Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy.Experimental and therapeutic medicine · 2018Article
- Treatment of membranous nephropathy: time for a paradigm shift.Nature reviews. Nephrology · 2017Review
- Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells.Pediatric nephrology (Berlin, Germany) · 2017Review
- Factors affecting the long-term outcomes of idiopathic membranous nephropathy.BMC nephrology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe efficacy and safety of immunosuppression for idiopathic membranous nephropathy (IMN) with nephrotic syndrome are still controversial. A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cochrane Library, PUBMED, EMBASE, Chinese Database, and Clinical Trial Registries (June 2012) were searched to identify RCTs investigating the effect of immunosuppression on adults with IMN and nephrotic syndrome.
resultsThis review was an update (36 RCTs, 1762 participants) of the 2004 version (18 RCTs, 1025 participants). Immunosuppression significantly reduced all-cause mortality or ESRD (15 RCTs, 791 participants; risk ratio, 0.58 [95% confidence interval, 0.36-0.95]; P=0.03). However, the result was not consistent when prespecified subgroup analyses were undertaken. Immunosuppression increased complete or partial remission (CR + PR) (16 RCTs, 864 participants; 1.31 [1.01-1.70]; P=0.04) but resulted in more withdrawals or hospitalizations (16 RCTs, 880 participants; 5.35 [2.19-13.02]; P=0.002). Corticosteroids combined with alkylating agents significantly reduced all-cause mortality or ESRD (8 RCTs, 448 participants; 0.44 [0.26-0.75]; P=0.002) and increased CR + PR (7 RCTs, 422 participants; 1.46 [1.13-1.89]; P=0.004) but led to more adverse events (4 RCTs, 303 participants; 4.20 [1.15-15.32]; P=0.03). Cyclophosphamide was safer than chlorambucil (3 RCTs, 147 participants; 0.48 [0.26-0.90]; P=0.02). Cyclosporine and mycophenolate mofetil failed to show superiority over alkylating agents. Tacrolimus and adrenocorticotropic hormone significantly reduced proteinuria.
conclusionsAlkylating agents plus corticosteroids had long-term and short-term benefits for adult IMN, but resulted in more withdrawals or hospitalizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.